<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879316</url>
  </required_header>
  <id_info>
    <org_study_id>HCochin</org_study_id>
    <nct_id>NCT04879316</nct_id>
  </id_info>
  <brief_title>Energy for Lymphocytes</brief_title>
  <acronym>ELY</acronym>
  <official_title>Analysis of Nutritional Biomarkers to Predict the Efficacy of Immunotherapy by Anti-PD/PDL1 Checkpoints Inhibitors in Metastatic Non-small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H么pital Cochin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>H么pital Cochin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      CERTIM is a cohort created in July 2015 to set up a multidisciplinary follow-up of cancer&#xD;
      patients treated with immune checkpoint inhibitors.&#xD;
&#xD;
      From the CERTIM cohort, we conducted a longitudinal, prospective, observational study (ELY)&#xD;
      in two tertiary university centers (Cochin hospital and European Georges Pompidou Hospital),&#xD;
      which included patients between August 2016 and October 2019 and ended follow-up in April&#xD;
      2020.&#xD;
&#xD;
      Patients were treated with nivolumab, at a dose of 3 mg/kg every 2 weeks, or pembrolizumab,&#xD;
      at a dose of 2mg/kg every 3 weeks. The investigators report findings from an evaluation of&#xD;
      rest energy expenditure (REE) assessed using indirect calorimetry in the outpatient setting&#xD;
      before treatment with checkpoints inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>6-month Progression-free survival</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>Calculated as the percentage of participants alive and without disease progression, as assessed by the Investigator using RECIST v1.1</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">144</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Progression, Disease</condition>
  <arm_group>
    <arm_group_label>adult patients with NSCLC initiating nivolumab or pembrolizumab</arm_group_label>
    <description>Patients underwent a multidisciplinary evaluation including consultation with an oncologist and a dietitian. Such an assessment includes subjective and objective parameters such as medical history, weight loss, current dietary intake (including energy and protein balance), physical examination and anthropometric measurements, functional and mental assessment, medications, Resting Energy Expenditure measurement using indirect calorimetry and laboratory values.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Resting Energy Expenditure measurement</intervention_name>
    <description>Resting Energy Expenditure measurement using indirect calorimetry</description>
    <arm_group_label>adult patients with NSCLC initiating nivolumab or pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with NSCLC initiating nivolumab or pembrolizumab in real-life conditions&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Stage IV histologically proven Non Small Cell Lung Cancer (NSCLC)&#xD;
&#xD;
          -  Monotherapy with nivolumab or pembrolizumab.&#xD;
&#xD;
          -  Patients were required to have measurable disease per the Response Evaluation Criteria&#xD;
             in Solid Tumors (RECIST), version 1.1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignancy other than NSCLC,&#xD;
&#xD;
          -  ALK or EGFR mutated NSCLC&#xD;
&#xD;
          -  Anticancer therapy or surgery within the past 2 weeks or inability to breathe under&#xD;
             the calorimetry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cochin Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>H么pital Cochin</investigator_affiliation>
    <investigator_full_name>Camille Levalois</investigator_full_name>
    <investigator_title>Co-investigator</investigator_title>
  </responsible_party>
  <keyword>cachexia</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>carcinoma</keyword>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Basal metabolism</keyword>
  <keyword>Energy expenditure</keyword>
  <keyword>inflammation</keyword>
  <keyword>6-month Progression free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

